Page last updated: 2024-10-31

midodrine and Hepatorenal Syndrome

midodrine has been researched along with Hepatorenal Syndrome in 37 studies

Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.

Hepatorenal Syndrome: Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the beneficial and harmful effects of terlipressin versus other vasoactive drugs for people with hepatorenal syndrome."8.95Terlipressin versus other vasoactive drugs for hepatorenal syndrome. ( Allegretti, AS; Gluud, LL; Goldin, AH; Israelsen, M; Jovani, M; Krag, A; Winter, RW, 2017)
"Midodrine along with albumin infusion, is helpful in the secondary prophylaxis of HRS-AKI and reduces the number of ascites tap."8.02Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites. ( Arora, A; Bansal, N; Kumar, A; Puri, P; Sharma, P; ShriHari, AA; Singla, V, 2021)
"To analyse the impact of treatment with midodrine after hepatorenal syndrome type 2 reversal induced by terlipressin on the prevention of hepatorenal syndrome recurrence."7.75Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study. ( Alessandria, C; Carello, M; Ceretto, S; Debernardi-Venon, W; Marzano, A; Rizzetto, M, 2009)
" Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure."6.69Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999)
"Terlipressin is an analog of the natural hormone arginine-vasopressin."6.44Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. ( Bendtsen, F; Borup, T; Krag, A; Møller, S, 2008)
"The adrenergic agonist midodrine improved circulatory and renal dysfunction when acutely administered in nonazotemic cirrhotic patients with ascites while its combination with octreotide has recently been proposed as an effective treatment of type 1 hepatorenal syndrome (HRS)."5.11The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. ( Al Bokharhii, J; Economou, M; Fotopoulos, A; Kalambokis, G; Katsaraki, A; Pappas, C; Tsianos, EV, 2005)
" We selected randomised controlled trials of adults (>18 years) with decompensated cirrhosis and type 1 hepatorenal syndrome that compared the efficacy of active vasoactive drugs (terlipressin, midodrine, octreotide, noradrenaline, and dopamine; alone or in combination) with placebo or each other."4.95Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. ( Chandar, AK; Facciorusso, A; Kamath, PS; Murad, MH; Muscatiello, N; Prokop, LJ; Singh, S, 2017)
"To evaluate the beneficial and harmful effects of terlipressin versus other vasoactive drugs for people with hepatorenal syndrome."4.95Terlipressin versus other vasoactive drugs for hepatorenal syndrome. ( Allegretti, AS; Gluud, LL; Goldin, AH; Israelsen, M; Jovani, M; Krag, A; Winter, RW, 2017)
"To review studies evaluating the use of midodrine and octreotide in hemodynamic complications of cirrhosis, including ascites and hepatorenal syndrome."4.85Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. ( Karwa, R; Woodis, CB, 2009)
"Midodrine along with albumin infusion, is helpful in the secondary prophylaxis of HRS-AKI and reduces the number of ascites tap."4.02Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites. ( Arora, A; Bansal, N; Kumar, A; Puri, P; Sharma, P; ShriHari, AA; Singla, V, 2021)
"The combination of octreotide, midodrine, and albumin (triple therapy) is used to treat hepatorenal syndrome (HRS) often as a bridge to liver transplantation (LT)."3.77Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. ( Rice, JP; Said, A; Skagen, C, 2011)
"To analyse the impact of treatment with midodrine after hepatorenal syndrome type 2 reversal induced by terlipressin on the prevention of hepatorenal syndrome recurrence."3.75Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study. ( Alessandria, C; Carello, M; Ceretto, S; Debernardi-Venon, W; Marzano, A; Rizzetto, M, 2009)
" Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure."2.69Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999)
"Terlipressin plus albumin was more efficacious than placebo plus albumin (odds ratio=4."2.58Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. ( Nanda, A; Reddy, R; Safraz, H; Salameh, H; Singal, AK, 2018)
" Future developments in dosage and administrative techniques for terlipressin may have an important role to play in maintaining clinical efficacy whilst improving tolerability in the management of HRS."2.58Hepatorenal syndrome: the clinical impact of vasoactive therapy. ( Colle, I; Laterre, PF, 2018)
"The hepatorenal syndrome is a well-recognized complication of advanced cirrhosis and is usually associated with an accelerated course to death unless liver transplantation is performed."2.53Emerging hepatic syndromes: pathophysiology, diagnosis and treatment. ( Bertino, G; Crisafulli, E; Demma, S; Koukias, N; Privitera, G; Purrello, F; Spadaro, L; Tsochatzis, EA, 2016)
"Terlipressin is an analog of the natural hormone arginine-vasopressin."2.44Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. ( Bendtsen, F; Borup, T; Krag, A; Møller, S, 2008)

Research

Studies (37)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (5.41)18.2507
2000's11 (29.73)29.6817
2010's19 (51.35)24.3611
2020's5 (13.51)2.80

Authors

AuthorsStudies
Bejjani, A1
Zhang, Y1
Behrens, A1
Murray, B1
Shah, N1
Pitre, T1
Kiflen, M1
Helmeczi, W1
Dionne, JC1
Rewa, O1
Bagshaw, SM1
Needham-Nethercott, N1
Alhazzani, W1
Zeraatkar, D1
Rochwerg, B1
Thomson, MJ1
Taylor, A1
Sharma, P3
Lok, AS1
Tapper, EB1
Hiruy, A1
Nelson, J1
Zori, A1
Morelli, G1
Cabrera, R1
Kamel, A1
Puri, P1
Bansal, N1
Singla, V1
Kumar, A1
ShriHari, AA1
Arora, A1
Facciorusso, A1
Chandar, AK1
Murad, MH1
Prokop, LJ1
Muscatiello, N1
Kamath, PS2
Singh, S1
Israelsen, M1
Krag, A2
Allegretti, AS1
Jovani, M1
Goldin, AH1
Winter, RW1
Gluud, LL1
Nanda, A1
Reddy, R1
Safraz, H1
Salameh, H1
Singal, AK1
Kalambokis, GN2
Baltayiannis, G1
Christodoulou, D1
Christou, L1
Colle, I1
Laterre, PF1
Stine, JG1
Wang, J1
Cornella, SL1
Behm, BW1
Henry, Z1
Shah, NL1
Caldwell, SH1
Northup, PG1
Hsu, SJ1
Huang, HC1
Sourianarayanane, A1
Raina, R1
Garg, G1
McCullough, AJ1
O'Shea, RS1
Maddukuri, G1
Cai, CX1
Munigala, S1
Mohammadi, F1
Zhang, Z1
Cavallin, M1
Merli, M1
Fasolato, S1
Toniutto, P1
Salerno, F1
Bernardi, M1
Romanelli, RG1
Colletta, C1
Salinas, F1
Di Giacomo, A1
Ridola, L1
Fornasiere, E1
Caraceni, P1
Morando, F1
Piano, S1
Gatta, A2
Angeli, P2
Graupera, I1
Ginès, P2
Velez, JC1
Kadian, M1
Taburyanskaya, M1
Bohm, NM1
Delay, TA1
Karakala, N1
Rockey, DC1
Nietert, PJ1
Goodwin, AJ1
Whelan, TP1
Glass, L1
Salman, TA1
Edrees, AM1
El-Said, HH1
El-Abd, OL1
El-Azab, GI1
Bertino, G1
Privitera, G1
Purrello, F1
Demma, S1
Crisafulli, E1
Spadaro, L1
Koukias, N1
Tsochatzis, EA1
Dong, T1
Aronsohn, A1
Gautham Reddy, K1
Te, HS1
Tsianos, EV2
Borup, T1
Møller, S1
Bendtsen, F1
Alessandria, C1
Debernardi-Venon, W1
Carello, M1
Ceretto, S1
Rizzetto, M1
Marzano, A1
Skagen, C2
Einstein, M1
Lucey, MR1
Said, A2
Karwa, R1
Woodis, CB1
Carl, DE1
Sanyal, A1
Rice, JP1
Hasper, D1
Jörres, A1
Olivera-Martinez, M1
Martinez, MO1
Sayles, H1
Vivekanandan, R1
D' Souza, S1
Florescu, MC1
Wong, F1
Pantea, L1
Sniderman, K1
Tong, W1
Hurley, S1
Hayashi, PH1
Kalambokis, G1
Economou, M1
Fotopoulos, A1
Al Bokharhii, J1
Pappas, C1
Katsaraki, A1
Esrailian, E1
Pantangco, ER1
Kyulo, NL1
Hu, KQ1
Runyon, BA1
Volpin, R1
Gerunda, G1
Craighero, R1
Roner, P1
Merenda, R1
Amodio, P1
Sticca, A1
Caregaro, L1
Maffei-Faccioli, A1
Gerbes, AL1
Gülberg, V1
Ortega, R1
Calahorra, B1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903): A Multicenter, Single-blind, Randomised Controlled Trial[NCT04028323]Phase 460 participants (Anticipated)Interventional2019-07-16Recruiting
A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Adaptive Dose-Ranging Study to Assess Safety and Efficacy of Intravenous OCE-205 in Adults Diagnosed With Cirrhosis With Ascites Who Have Developed Hepatorenal Syndrome-Acute Kidney Injury (HRS[NCT05309200]Phase 247 participants (Actual)Interventional2022-04-28Completed
Study on the Effect of Terlipressin on Recovery of Liver Function After Hepatectomy: a Multicenter Randomized Controlled Study[NCT04221672]Phase 386 participants (Anticipated)Interventional2019-11-07Recruiting
Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients[NCT05621005]Phase 2104 participants (Actual)Interventional2019-03-01Completed
Comparison of Endoscopic Band Ligation Plus 24-hour Versus 72-hour Terlipressin Therapy for the Control of Acute Variceal Bleeding in Patients With Liver Cirrhosis at a Tertiary Center in Mexico[NCT05331768]109 participants (Actual)Interventional2021-01-01Completed
Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation[NCT00839358]Phase 4199 participants (Actual)Interventional2008-08-31Completed
Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis[NCT00108355]Phase 429 participants (Actual)Interventional2003-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Development of Post-paracentesis Circulatory Dysfunction (PCD)

Defined as an increase in Plasma Renin Activity (PRA) by >50% from baseline to a level > 4 ng/mL/h at post-paracentesis day (NCT00108355)
Timeframe: 6 days after paracentesis

Interventionparticipants (Number)
Albumin (Control Group)2
Vasoconstrictor (Treatment Group)2

Time to Recurrence of Ascites.

Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group) (NCT00108355)
Timeframe: Variable depending on the patient, average 10 days

Interventiondays (Median)
Albumin (Control Group)10
Vasoconstrictor (Treatment Group)8

Reviews

13 reviews available for midodrine and Hepatorenal Syndrome

ArticleYear
The Comparative Effectiveness of Vasoactive Treatments for Hepatorenal Syndrome: A Systematic Review and Network Meta-Analysis.
    Critical care medicine, 2022, 10-01, Volume: 50, Issue:10

    Topics: Hepatorenal Syndrome; Humans; Midodrine; Network Meta-Analysis; Norepinephrine; Octreotide; Terlipre

2022
Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis.
    Digestive diseases and sciences, 2020, Volume: 65, Issue:5

    Topics: Adult; Albumins; Anti-Bacterial Agents; Dopamine; Drug Therapy, Combination; Female; Hepatorenal Syn

2020
Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
    The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:2

    Topics: Dopamine; Drug Therapy, Combination; Gastrointestinal Agents; Hepatorenal Syndrome; Humans; Lypressi

2017
Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
    The Cochrane database of systematic reviews, 2017, 09-27, Volume: 9

    Topics: Antihypertensive Agents; Dopamine; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Norepinephrin

2017
Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.
    Journal of clinical gastroenterology, 2018, Volume: 52, Issue:4

    Topics: Albumins; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Infusions, Intravenous; Midodrine

2018
Hepatorenal syndrome: the clinical impact of vasoactive therapy.
    Expert review of gastroenterology & hepatology, 2018, Volume: 12, Issue:2

    Topics: Biomarkers; Creatinine; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Norepinephrine; Octreoti

2018
Management of ascites in patients with liver cirrhosis: recent evidence and controversies.
    Journal of the Chinese Medical Association : JCMA, 2013, Volume: 76, Issue:3

    Topics: Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodrine; Portasystemic Shunt, T

2013
Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.
    Internal and emergency medicine, 2016, Volume: 11, Issue:7

    Topics: Acute Kidney Injury; Adrenal Insufficiency; Ascites; Creatinine; Evidence-Based Medicine; Hepatorena

2016
Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
    Advances in therapy, 2008, Volume: 25, Issue:11

    Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynamics; Hepatorenal Syndrome; Hum

2008
Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
    The Annals of pharmacotherapy, 2009, Volume: 43, Issue:4

    Topics: Ascites; Hemodynamics; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Midodrine; Octreotide; Treatme

2009
The management of hepatorenal syndrome.
    Minerva gastroenterologica e dietologica, 2009, Volume: 55, Issue:2

    Topics: Albumins; Drug Therapy, Combination; Evidence-Based Medicine; Hepatorenal Syndrome; Humans; Liver Ci

2009
New insights into the management of hepato-renal syndrome.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 3

    Topics: Disease Management; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Norepinephrine; Renal Dialys

2011
[Vasoconstrictors in the treatment of hepatorenal syndrome].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2002, Volume: 22 Suppl 5

    Topics: Adrenergic alpha-Agonists; Albumins; Drug Evaluation; Drug Therapy, Combination; Hepatorenal Syndrom

2002

Trials

7 trials available for midodrine and Hepatorenal Syndrome

ArticleYear
Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial.
    Annals of hepatology, 2018, Mar-01, Volume: 17, Issue:2

    Topics: Aged; Albumins; Drug Therapy, Combination; Female; Hepatorenal Syndrome; Hospital Mortality; Humans;

2018
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:2

    Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore

2015
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:2

    Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore

2015
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:2

    Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore

2015
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:2

    Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore

2015
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:2

    Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore

2015
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:2

    Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore

2015
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:2

    Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore

2015
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:2

    Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore

2015
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:2

    Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore

2015
Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis.
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:7

    Topics: Adult; Bacterial Infections; Drug Therapy, Combination; Female; Hemodynamics; Hepatorenal Syndrome;

2016
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Hepatology (Baltimore, Md.), 2004, Volume: 40, Issue:1

    Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Blood Volume; Creatinine; Drug Therapy, C

2004
The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:4

    Topics: Administration, Oral; Adrenergic alpha-Agonists; Adult; Aged; Aldosterone; Blood Flow Velocity; Drug

2005
Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Hepatology (Baltimore, Md.), 1999, Volume: 29, Issue:6

    Topics: Aldosterone; Ascites; Blood Pressure; Diuresis; Electrolytes; Gastrointestinal Agents; Glomerular Fi

1999
[Hepatorenal syndrome: a new therapeutic approach?].
    Zeitschrift fur Gastroenterologie, 1999, Volume: 37, Issue:9

    Topics: Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Kidney Function Tests; Midodrine; Octreotid

1999

Other Studies

17 other studies available for midodrine and Hepatorenal Syndrome

ArticleYear
Droxidopa in the Management of Hepatorenal Syndrome.
    Journal of pharmacy practice, 2023, Volume: 36, Issue:4

    Topics: Droxidopa; Hepatorenal Syndrome; Humans; Male; Middle Aged; Midodrine; Norepinephrine; Octreotide

2023
Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate.
    European journal of gastroenterology & hepatology, 2021, Volume: 33, Issue:1

    Topics: Albumins; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Midodrine; Octre

2021
Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites.
    European journal of gastroenterology & hepatology, 2021, 12-01, Volume: 33, Issue:1S Suppl 1

    Topics: Acute Kidney Injury; Albumins; Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Midodrine; Pi

2021
Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1.
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:12

    Topics: Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Octreotide; Retrospec

2017
Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients.
    International urology and nephrology, 2014, Volume: 46, Issue:4

    Topics: Aged; Albumins; Female; Gastrointestinal Agents; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Live

2014
Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study.
    Digestive diseases and sciences, 2014, Volume: 59, Issue:2

    Topics: Albumins; Arterial Pressure; Disease Progression; Disease-Free Survival; Drug Therapy, Combination;

2014
Hepatorenal syndrome: The last pieces of the puzzle or not yet?
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:2

    Topics: Albumins; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Midodrine; Octreotide

2015
Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure.
    Nephron, 2015, Volume: 131, Issue:3

    Topics: Acute Kidney Injury; Aged; Arterial Pressure; Creatinine; End Stage Liver Disease; Female; Hepatoren

2015
Evidence-Based Therapeutic Options for Hepatorenal Syndrome.
    Gastroenterology, 2016, Volume: 150, Issue:4

    Topics: Albumins; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Midodrine; Octreotide

2016
Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:12

    Topics: Acute Kidney Injury; Aged; Anti-Infective Agents; Case-Control Studies; End Stage Liver Disease; Fem

2016
Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:2

    Topics: Adrenergic alpha-Agonists; Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodr

2008
Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2009, Volume: 41, Issue:4

    Topics: Case-Control Studies; Drug Administration Schedule; Female; Hepatorenal Syndrome; Humans; Lypressin;

2009
Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
    Journal of clinical gastroenterology, 2009, Volume: 43, Issue:7

    Topics: Adrenergic alpha-Agonists; Adult; Aged; Albumins; Cohort Studies; Disease Progression; Drug Therapy,

2009
Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin.
    Transplantation, 2011, May-27, Volume: 91, Issue:10

    Topics: Adult; Albumins; Case-Control Studies; Chi-Square Distribution; Female; Glomerular Filtration Rate;

2011
Hepatorenal syndrome: are we missing some prognostic factors?
    Digestive diseases and sciences, 2012, Volume: 57, Issue:1

    Topics: Albumins; Alcoholism; Autoimmune Diseases; Creatinine; End Stage Liver Disease; Female; Hepatitis C;

2012
Reconsidering hepatorenal syndrome. Throw in the towel? Not so fast!
    Postgraduate medicine, 2004, Volume: 116, Issue:6

    Topics: Administration, Oral; Adult; Albumins; Creatinine; Drug Therapy, Combination; Fatal Outcome; Gastroi

2004
Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:3

    Topics: Creatinine; Drug Therapy, Combination; Female; Gastrointestinal Agents; Hepatorenal Syndrome; Humans

2007